Browsing Tag
Farxiga
8 posts
AstraZeneca FY2025 results analysis: How oncology scale, China exposure, and pipeline depth are reshaping long-term earnings power
AstraZeneca’s FY2025 results reveal what’s driving growth, where risks are building, and how pipeline depth could shape earnings beyond 2030. Read the full analysis.
AstraZeneca just joined the direct-to-consumer drug race — here’s what it means for patients and rivals
AstraZeneca launches AstraZeneca Direct in the U.S. with up to 70% discounts. Explore how this direct-to-consumer model could reshape drug access.
AstraZeneca reports strong FY 2024 results with robust revenue growth driven by oncology and biopharmaceuticals
AstraZeneca’s financial performance for fiscal year 2024 reflects impressive growth, with the pharmaceutical giant reporting a 21% surge…
AstraZeneca wraps up $1.8bn acquisition of CinCor Pharma
AstraZeneca has closed the previously announced $1.8 billion acquisition of US biopharmaceutical company CinCor Pharma. Under the terms…
AstraZeneca to acquire US biopharma company CinCor Pharma for $1.8bn
AstraZeneca has agreed to acquire CinCor Pharma for a transaction value of around $1.8 billion, which includes an…
AstraZeneca’s Forxiga wins approval in China for heart failure treatment
AstraZeneca has announced that its drug, Forxiga (dapagliflozin), has received approval from the Chinese National Medical Products Administration…
AstraZeneca’s Farxiga receives FDA breakthrough therapy designation for chronic kidney disease treatment
AstraZeneca’s Farxiga (dapagliflozin), a leading drug in the management of chronic kidney disease (CKD), has been granted Breakthrough…
Farxiga : AstraZeneca gets FDA fast track status for heart failure after MI
AstraZeneca has secured fast track designation for Farxiga (dapagliflozin) in the US for its use in reducing the…